Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells

Mohsan Saeed1, Troels K H Scheel, Judith M Gottwein

  • 1Laboratory of Virology and Infectious Diseases, Center for the Study of Hepatitis C, The Rockefeller University, New York, New York, USA.

Insights

Researchers developed new cell culture systems for hepatitis C virus (HCV) genotypes 3a and 4a. These functional replicons are crucial for discovering pan-genotype HCV inhibitors and advancing antiviral therapies.

Area of Science:

  • Virology
  • Hepatology
  • Drug Discovery

Background:

  • Hepatitis C virus (HCV) treatment advances continue, yet pan-genotype inhibitors are needed.
  • Existing in vitro replication systems are limited to HCV genotypes 1a, 1b, and 2a.
  • Developing systems for other genotypes is essential for comprehensive antiviral research.

Purpose of the Study:

  • To establish functional in vitro replication systems for Hepatitis C virus (HCV) genotypes 3a and 4a.
  • To facilitate the development of pan-genotype HCV inhibitors.
  • To enable high-throughput screening of antiviral compounds against diverse HCV strains.

Main Methods:

  • Generated G418-selectable subgenomic replicons for HCV genotypes 3a (S52) and 4a (ED43).
  • Identified and incorporated cell culture adaptive mutations (S2210I and R2882G) in NS3 protein.
  • Modified replicons to express firefly luciferase-neomycin phosphotransferase fusion protein for stable cell lines.

Main Results:

  • Successfully established functional replicons for HCV genotypes 3a and 4a in Huh-7.5 cells.
  • Confirmed RNA replication and viral protein expression.
  • Demonstrated detection of antiviral compound inhibition (IFN-β, NS3 protease inhibitor, NS5B polymerase inhibitor) via luciferase activity.

Conclusions:

  • Established functional replicons for HCV genotypes 3a and 4a, expanding the available research tools.
  • These replicons are valuable for evaluating inhibitors against a broader range of HCV genotypes.
  • This work contributes to the development of pan-genotype HCV antiviral therapies.